Thermo Fisher, Hologic ride wave of COVID-19 test demand, for now

Hologic and Thermo Fisher Scientific reported earnings benefiting from strong demand for their respective SARS-CoV-2 assays. Hologic's fourth-quarter revenue of $1.32 billion beat the Street by $280 million, while Thermo Fisher's third-quarter revenue of $9.33 billion beat analyst estimates by $920 million.